Valuation: PFIZER

Market Cap 14TCr 14TCr 12TCr 12TCr 11TCr 20TCr 13,74900Cr 20TCr 1,37600Cr 54TCr 6,73400Cr 54TCr 52TCr 23,18100Cr P/E 2026 *
12.7x
P/E 2027 * 13.2x
Enterprise Value 19TCr 19TCr 17TCr 15TCr 14TCr 27TCr 18,49700Cr 28TCr 1,85100Cr 73TCr 9,05900Cr 72TCr 71TCr 31,18500Cr EV / Sales 2026 *
3.11x
EV / Sales 2027 * 3.14x
Free-Float
59.06%
Yield 2026 *
6.89%
Yield 2027 * 6.96%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 60 02/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2007
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.85%-0.80%+52.79%+161.33% 1,05100Cr
+1.23%-1.53%+54.58%+59.08% 61TCr
+0.04%+2.58%+34.47%+86.33% 45TCr
+0.78%-0.71%+29.28%+24.10% 33TCr
+1.41%+0.58%+35.44%+40.67% 28TCr
-0.27%-1.87%+22.34%+22.51% 26TCr
-1.76%+2.37%-20.43%-38.00% 22TCr
-1.42%+0.80%+24.27%+57.50% 20TCr
-1.48%+3.43%+24.08%+71.67% 17TCr
Average -0.07%+0.54%+28.54%+53.91% 39.72TCr
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2026 *2027 *
Net sales 6.17TCr 6.17TCr 5.4TCr 4.98TCr 4.59TCr 8.65TCr 5,94500Cr 8.84TCr 60TCr 23TCr 2,91200Cr 23TCr 23TCr 10,02400Cr 5.92TCr 5.92TCr 5.17TCr 4.77TCr 4.4TCr 8.29TCr 5,70100Cr 8.48TCr 57TCr 22TCr 2,79200Cr 22TCr 22TCr 9,61200Cr
Net income 1.06TCr 1.06TCr 928.7Cr 856.98Cr 789.92Cr 1.49TCr 1,02300Cr 1.52TCr 10TCr 4.03TCr 50TCr 3.99TCr 3.9TCr 1,72500Cr 1.03TCr 1.03TCr 897.31Cr 828.01Cr 763.22Cr 1.44TCr 99TCr 1.47TCr 9.9TCr 3.89TCr 48TCr 3.86TCr 3.77TCr 1,66700Cr
Net Debt 4.93TCr 4.93TCr 4.31TCr 3.98TCr 3.66TCr 6.91TCr 4,74700Cr 7.06TCr 48TCr 19TCr 2,32500Cr 19TCr 18TCr 8,00400Cr 4.32TCr 4.32TCr 3.77TCr 3.48TCr 3.21TCr 6.05TCr 4,15700Cr 6.18TCr 42TCr 16TCr 2,03600Cr 16TCr 16TCr 7,00900Cr
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A